Gene therapy using Aβ variants for amyloid reduction.

Abstract

Numerous aggregation inhibitors have been developed with the goal of blocking or reversing toxic amyloid formation in vivo. Previous studies have used short peptide inhibitors targeting different amyloid β (Aβ) amyloidogenic regions to prevent aggregation. Despite the specificity that can be achieved by peptide inhibitors, translation of these strategies has been thwarted by two key obstacles: rapid proteolytic degradation in the bloodstream and poor transfer across the blood-brain barrier. To circumvent these problems, we have created a minigene to express full-length Aβ variants in the mouse brain. We identify two variants, F20P and F19D/L34P, that display four key properties required for therapeutic use: neither peptide aggregates on its own, both inhibit aggregation of wild-type Aβ in vitro, promote disassembly of pre-formed fibrils, and diminish toxicity of Aβ oligomers. We used intraventricular injection of adeno-associated virus (AAV) to express each variant in APP/PS1 transgenic mice. Lifelong expression of F20P, but not F19D/L34P, diminished Aβ levels, plaque burden, and plaque-associated neuroinflammation. Our findings suggest that AAV delivery of Aβ variants may offer a novel therapeutic strategy for Alzheimer's disease. More broadly our work offers a framework for identifying and delivering peptide inhibitors tailored to other protein-misfolding diseases.

• Authors: Kyung-Won Park, Caleb A Wood, Jun Li, Bethany C Taylor, SaeWoong Oh, Nicolas L Young, Joanna L Jankowsky
• Journal: Molecular therapy : the journal of the American Society of Gene Therapy (Mol Ther) Vol. 29 Issue 7 Pg. 2294-2307 (07 07 2021) ISSN: 1525-0024 [Electronic] United States
• PMID: 33647457 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Chemical References

• Amyloid beta-Peptides

Topics

• Alzheimer Disease (genetics, pathology, therapy)
• Amyloid beta-Peptides (antagonists & inhibitors, genetics, metabolism)
• Animals
• Brain (metabolism)
• Dependovirus (genetics)
• Female
• Genetic Therapy
• Genetic Vectors (administration & dosage, genetics)
• Humans
• Male
• Mice
• Mice, Inbred ICR
• Mice, Transgenic
• Mutation
• Plaque, Amyloid (genetics, metabolism, therapy)